Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Jnj-38877605. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 20/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 4/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 3/20 | 1.00 |
| ▸ | NQO2 | P16083 | 2/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.65 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.65 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.65 |
| ▸ | PDE2A | O00408 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | PDE1A | P54750 | 1/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.63 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jnj-38877605 SCHEMBL30028214 | 1.00 | MET (1.00) | METPDE3APDE3BNQO2PIP4K2C | |
| Jnj-38877605 SCHEMBL29358742 | 1.00 | MET (1.00) | METPDE3APDE3BNQO2PIP4K2C | |
| Jnj-38877605 SCHEMBL19366742 | 0.91 | MET (1.00) | METPDE3APDE3BNQO2PIP4K2C | |
| SCHEMBL1658513 | 0.88 | MET (0.78) | METPDE3APDE3BNQO2PIP4K2C | |
| SCHEMBL19338435 | 0.87 | MET (0.77) | METPDE3APDE3BNQO2PIP4K2C | |
| SCHEMBL15309750 | 0.87 | MET (1.00) | METPDE3APDE3BNQO2PIP4K2C | |
| SCHEMBL2497303 | 0.87 | MET (0.76) | METPDE3APDE3BNQO2PIP4K2C | |
| SCHEMBL19366750 | 0.86 | MET (0.75) | METPDE3APDE3BNQO2PIP4K2C | |
| SCHEMBL17768402 | 0.85 | MET (0.74) | METPDE3APDE3BNQO2PIP4K2C | |
| SCHEMBL12049490 | 0.85 | MET (0.84) | METPDE3APDE3BNQO2PIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848034-B1 | CMET-INHIBITORS FOR USE IN DELAYING THE EMERGENCE IN RESISTANCE TO FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2025-02-12 | — | — | EP | claimed |
| US-11918576-B2 | Combination of an FGFR inhibitor and a CMET inhibitor | ASTEX THERAPEUTICS LTD (GB) | 2024-03-05 | — | — | US | claimed |
| EP-3848034-A1 | CMET-INHIBITORS FOR USE IN DELAYING THE EMERGENCE IN RESISTANCE TO FGFR INHIBITORS | Astex Therapeutics Limited (GB) | 2021-07-14 | — | — | EP | claimed |
| US-20210038598-A1 | COMBINATIONS | ASTEX THERAPEUTICS LTD (GB) | 2021-02-11 | — | — | US | claimed |
| EP-3122358-B1 | COMBINATIONS OF FGFR- AND CMET-INHIBITORS FOR THE TREATMENT OF CANCER | ASTEX THERAPEUTICS LTD (GB) | 2020-12-16 | — | — | EP | claimed |
| US-10716787-B2 | Combinations | ASTEX THERAPEUTICS LTD (GB) | 2020-07-21 | — | — | US | claimed |
| US-20180296558-A1 | COMBINATIONS | ASTEX THERAPEUTICS LTD (GB) | 2018-10-18 | — | — | US | claimed |
| US-10085982-B2 | Combinations | ASTEX THERAPEUTICS LTD (GB) | 2018-10-02 | — | — | US | claimed |
| US-20170119763-A1 | COMBINATIONS | ASTEX THERAPEUTICS LTD (GB) | 2017-05-04 | — | — | US | claimed |
| EP-3122358-A1 | COMBINATIONS | Astex Therapeutics Ltd. (GB) | 2017-02-01 | — | — | EP | claimed |
| WO-2015144804-A1 | COMBINATIONS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-01 | — | — | WO | claimed |
| WO-2026102277-A1 | COMBINATION THERAPIES COMPRISING IKZF2 DEGRADER COMPOUNDS | Plexium, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4730355-A1 | TYPING SYSTEM AND METHOD FOR HR-POSITIVE/HER2-NEGATIVE BREAST CANCER | Lumitype Medical (Huzhou) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| EP-4541381-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2026-02-04 | — | — | EP | disclosed |
| WO-2008049930-A2 | A METHOD FOR PROFILING KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-02 | — | — | WO | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| WO-2007075567-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10085982-B2 | Combinations | FGFR3, FGFR1, FGFR2 | MET 10/4885PDE3A 1840/4885PDE3B 2006/4885 |
| US-11918576-B2 | Combination of an FGFR inhibitor and a CMET inhibitor | FGFR3, FGFR1, FGFR2 | MET 5/4885PDE3A 2186/4885PDE3B 2412/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | MET 1078/4885PDE3A 4727/4885PDE3B 4870/4885 |
| US-20180296558-A1 | COMBINATIONS | FGFR3, FGFR1, FGFR2 | MET 10/4885PDE3A 1840/4885PDE3B 2006/4885 |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | MET 2/4885PDE3A 906/4885PDE3B 859/4885 |
| US-20210038598-A1 | COMBINATIONS | FGFR3, FGFR1, FGFR2 | MET 9/4885PDE3A 1611/4885PDE3B 1783/4885 |
| US-20170119763-A1 | COMBINATIONS | FGFR3, FGFR1, FGFR2 | MET 10/4885PDE3A 1840/4885PDE3B 2006/4885 |
| US-10716787-B2 | Combinations | FGFR3, FGFR1, FGFR2 | MET 10/4885PDE3A 1840/4885PDE3B 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.